ArticlemicroPublication biology2026
Effects of Vitamin C Supplementation on Tetrabenazine Treatment in a Caenorhabditis elegans Huntington's Disease Model.
Article in microPublication biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Tetrabenazine, a VMAT2 inhibitor, is widely used to treat chorea in Huntington's disease by depleting monoamine neurotransmitters, particularly dopamine. However, this mechanism may indirectly increase oxidative stress due to enhanced metabolism and auto‑oxidation of cytosolic monoamines, generating reactive oxygen species. Using Caenorhabditis elegans polyglutamine models, this study investigated the effects of tetrabenazine and vitamin C supplementation on survival. These results indicate that tetrabenazine reduces survival, while vitamin C, a known antioxidant, mitigates these effects and improves outcomes, particularly in pathogenic poly‑Q strains. Our findings suggest that antioxidant supplementation may counteract tetrabenazine‑associated oxidative stress and enhance therapeutic efficacy in neurodegenerative disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.